SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
February 1, 2013 (January 28, 2013)
PROTEA BIOSCIENCES GROUP, INC.
(Exact name of registrant as specified in
|(State or other jurisdiction of
incorporation or organization)
|(Commission File Number)
||(IRS Employer Identification No.)|
955 Hartman Run Road
Morgantown, West Virginia 26507
(Address of principal executive offices)
(Registrant’s telephone number, including
(Former name or former address, if
changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|Item 5.02||Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective January 28,
2013, Johan M. (Thijs) Spoor and Josiah T. Austin were appointed by the board of directors (the "Board") of Protea Biosciences
Group, Inc. (the "Company") to serve as directors to fill existing vacancies on the board. Neither Mr. Spoor nor Mr.
Austin have any family relationship with any of the officers or directors of
the Company and there is no arrangement or understanding between Mr. Spoor or Mr. Austin and any third party pursuant to which
they were selected as directors. Mr. Spoor has not had any transaction with the Company during the past fiscal year through the
present that would require reporting pursuant to Item 404(a) of Regulation S-K.
Austin is the managing member of El Coronado Holdings, LLC. During the fiscal year ended December 31, 2012, the Company
issued and sold an aggregate of 2,000,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common
Stock”) and Warrants (as defined below) to purchase 1,500,000 shares of Common Stock for aggregate gross proceeds of $1,000,000
to El Coronado Holdings, LLC in accordance with the terms and conditions of that certain Securities Purchase Agreement, dated November
20, 2012. The warrants (the “Warrants”) are exercisable for a term of five years from the issue date of the Warrants,
at an exercise price of $1.10 per share.
In addition, on January
3, 2013 (the "Issue Date") the Company issued to El Coronado Holdings, LLC (the "Holder”) for an aggregate
purchase price equal to $125,000 (1) a convertible promissory note (the "Note") in an aggregate principal amount equal
to $125,000 (the "Principal Amount") and (2) a warrant (the "Note Warrant") to purchase 187,500 shares of Common
Stock of the Company. The Note accrues simple interest at a rate of 10% per annum and is due and payable on the earlier to occur
of (i) April 1, 2013, or (ii) when declared due and payable by the holder upon the occurrence of an event of default. The Note
Warrant is exercisable at an exercise price of $1.10 per share anytime after the Issue Date until the earlier of (i) a Qualified
Public Offering (as more specifically defined in the Note Warrant) or (ii) 5:00 p.m. EST on the fifth anniversary of the Issue
Date. As of the date hereof the entire Principal Amount remains outstanding and no amounts have been paid on the Note.
Spoor and Mr. Austin are each entitled to reimbursement for reasonable out of pocket expenses related to their service as members
of the Board, subject to the terms and conditions of the Company’s expense reimbursement policies.
Mr. Spoor or Mr. Austin has been appointed to a committee.
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|Dated: February 1, 2013
Chief Executive Officer